High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer

◆ TRIAL DATA

The phase III SOLARIS trial found median PFS was 11.8 months with high-dose vitamin D3 (8,000 IU then 4,000 IU daily) versus 10.3 months with standard-dose (400 IU daily) when added to chemotherapy plus bevacizumab in 455 previously untreated mCRC patients. (JAMA / The ASCO Post)